SCHEDULE 13G/A: Rubric Capital Management Discloses 9.34% Stake in Collegium Pharmaceutical

Rubric Capital Management LP and its Managing Member, David Rosen, have disclosed a beneficial ownership of 9.34% in Collegium Pharmaceutical, Inc., holding 3,000,000 shares of common stock.

Summary

• Rubric Capital Management LP and David Rosen, its Managing Member, have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses beneficial ownership of 3,000,000 shares of Common Stock in Collegium Pharmaceutical, Inc.
• This represents 9.34% of Collegium Pharmaceutical's outstanding common stock.
• The percentage is based on 32,131,798 shares outstanding as of March 25, 2025, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A.
• Rubric Capital Management LP is an investment adviser, and David Rosen is an individual and holding company.
• Both reporting persons share voting and dispositive power over all 3,000,000 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently suggests positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates significant institutional investment interest in Collegium Pharmaceutical, Inc., a pharmaceutical company. Such disclosures are common for investment firms taking passive stakes in publicly traded companies within the healthcare or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Rubric Capital Management and David Rosen may be viewed positively by other shareholders, indicating confidence from a notable investment firm. It could also signal potential future engagement or influence, although the filing states a passive intent.

Key Dates

Keywords

Collegium Pharmaceutical, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Ownership, SEC Filing